SCHEMBL247696

SCHEMBL247696

Cc1c(-c2ccccn2)nc2cc(F)cc(F)c2c1Nc1cc(N2CCOCC2)ncc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.60
PIK3CA P42336 10/20 0.46
RAF1 P04049 4/20 0.41
BRAF P15056 4/20 0.41
MAPK13 O15264 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK11 Q15759 1/20 0.41
MAPK14 Q16539 1/20 0.41
MTOR P42345 1/20 0.39
SMG1 Q96Q15 1/20 0.39
SYK P43405 1/20 0.39
PIK3CB P42338 2/20 0.38
ATR Q13535 1/20 0.38
ATRIP Q8WXE1 1/20 0.38
CNR2 P34972 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL248057 0.93 PIK3CD (0.64) PIK3CDPIK3CASYKPIK3CBPIK3CG
SCHEMBL248499 0.93 PIK3CD (0.60) PIK3CDPIK3CASYKPIK3CBPIK3CG
SCHEMBL247845 0.92 PIK3CD (0.66) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL247989 0.91 PIK3CD (0.68) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL247296 0.90 PIK3CD (0.62) PIK3CDPIK3CARAF1BRAFPIK3CB
SCHEMBL247950 0.90 PIK3CD (0.58) PIK3CDPIK3CARAF1BRAFPIK3CB
SCHEMBL252021 0.89 PIK3CD (0.68) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL246488 0.89 PIK3CD (0.64) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL246384 0.89 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL247947 0.89 PIK3CD (0.65) PIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588471-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2013-04-11 US disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003283-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090323-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CD 24/4885PIK3CA 28/4885RAF1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.